Will 'Financial Toxicity’ Weigh Down 1L NSCLC Win For Tagrisso In India?
Executive Summary
The price factor could potentially shrink the patient pool in first line non-small cell lung cancer for Tagrisso in largely out-of-pocket markets like India, though AstraZeneca has put in place a patient assistance program in this market for those can’t afford the medicine.